AAC
VPHM

Asset Advisors Corp’s VIROPHARMA INC VPHM Stock Holding History

Asset Advisors Corp’s Portfolio VPHM Stock Details VPHM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-150
Closed -$6K – 157
2013
Q3 		$6K Hold
150
– – ﹤0.01% 147
2013
Q2 		$4K Buy
+150
New +$3.96K ﹤0.01% 161

Other funds holding VPHM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Asset Advisors Corp's VPHM Position: Q4 2013 in Review

Asset Advisors Corp sold out of VIROPHARMA INC (VPHM) in Q4 2013, closing a stake of 150 shares — an estimated $6K sold.

Asset Advisors Corp first reported a position in VPHM in Q2 2013 and held it in 2 quarters. The position peaked at $6K in Q3 2013. 172 funds tracked by Wall St. Rank hold VPHM as of Q4 2013.

  • Asset Advisors Corp reported no remaining VIROPHARMA INC position as of Q4 2013 after selling out during the quarter.
  • Asset Advisors Corp sold 150 VIROPHARMA INC shares in Q4 2013, an estimated $6K.
  • Asset Advisors Corp first reported a position in VIROPHARMA INC in Q2 2013 and held it in 2 quarters.
  • Asset Advisors Corp's VIROPHARMA INC position peaked at $6K in Q3 2013.
  • 172 funds tracked by Wall St. Rank held VIROPHARMA INC as of Q4 2013.

Based on Asset Advisors Corp's 13F filing for Q4 2013, filed 24 Jan 2014.